Sign inJoin waitlistJoin the waitlist

Branimir Sikic

Hematology & Oncology

Credentials: · ·

History

Hematology and Medical Oncology
1975–1978
MedStar Georgetown University Hospital
1972–1975
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1968–1972
Georgetown University
1964–1968

Research

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Journal of Clinical Oncology · 2019 · First of 30 authors · 529 citations
Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death
Review · Journal of Clinical Oncology · 1999 · 478 citations
Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity
Blood · 1991 · Last of 3 authors · 445 citations

George Fisher
25 papers · 5 as a fellow
Norman Lacayo
13 papers
Ranjana Advani
11 papers · 1 as a fellow
DJ
Dejan Juric
9 papers · 4 as a resident
DL
Derick Lau
9 papers
Markus Bredel
9 papers · 8 as a fellow
NB
Nathalie Brophy
8 papers
Nelson Chao
8 papers
Robert Carlson
8 papers · 3 as a fellow
Griffith Harsh
7 papers
Hannes Vogel
7 papers
SB
Samuel Ballon
7 papers

Grants

Stanford University NCTN- Network Lead Academic Site
National Cancer Institute · U10
PI · $2.8M · Stanford University
2014–2019
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers
National Cancer Institute · R01
Contact PI · $2M · Stanford University
2014–2018
Stanford Cancer Institute
National Cancer Institute · P30
Project lead · $460.3K · Stanford University
2010–2016
Taxane Resistance in Breast and Ovarian Cancer Cells
National Cancer Institute · R01
Contact PI · $1.5M · Stanford University
2007–2013

Clinical trials

Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
Principal investigator · Completed · Phase 1
Branimir Sikic
2006–2010
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
Principal investigator · Terminated · Phase 1
National Cancer Institute (NCI)
2003
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
Study chair · Terminated · Phase 1, Phase 2
George Albert Fisher
2004–2009
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Study chair · Completed · Phase 2
Stanford University
2001–2006